IJCRT.ORG

ISSN: 2320-2882



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

An Overview on Clinical Effectiveness of Curcumin in Oral Submucous Fibrosis

Ambade Vaishali^{1*}, Lahankar Madhukar²

1* - Corresponding author. Professor and HOD, Shalakyatantra, Bharati Ayurved Medical College and Hospital, Durg (C.G.) and Ph.D. Scholar, Shalakyatantra, Government Ayurved College and Hospital Nagpur, e-mail id - ambadevaishali5@gmail.com.

2 – Ex-Professor and HOD Shalakyatrantra, Government Ayurved College and Hospital Nagpur

Abstract

Oral submucous fibrosis (OSMF) is the condition affecting the oral health characterized by restricted mouth opening. This condition greatly interferes with the patient's quality of life. It is becoming a major health issue in Indian population mainly due to the habit of areca nut chewing. Some cases of OSMF have the tendency to progress into malignancy. No definitive treatment is available for this condition at present. The objective of this study was to analyse the clinical efficacy of curcumin in OSMF based on the available literature. The articles published in PubMed and Cochrane from the duration of 2011 to 2021 were searched and reviewed for the expected outcome. The review was suggestive of the significant result of the curcumin in oral submucous fibrosis especially in symptoms like restricted mouth opening and burning sensation. Multicentric studies with large sample size and long duration of follow ups are needed to emphasize the effect of curcumin in OSMF.

Keywords: Turmeric, OSMF. Oral health, restricted mouth opening

1. Introduction

Oral submucous fibrosis is the condition of buccal mucosa characterized by abnormal collagen deposition causing ulceration, burning sensation, xerostomia and restricted mouth opening. It is becoming a major health issue in India having prevalence rate of 6.42 per 1000.^[1] There are multiple causative factors for OSMF like areca nut chewing spicy food consumption, especially chilly, nutritional deficiencies etc.^[2] Chewing betel nut

and tobacco together increases the incidence of OSF.^[3] In Indian population this combination is frequently consumed now a days causing the increase in cases of OSMF. 1.5 to 15% cases of OSMF progress to malignancy hence indirectly contribute to significant mortality.^[4] There is no definite treatment for OSMF at present. Various medical therapies are tried by different researchers like fibrinolytic agents, systemic, topical and intralesional vasodilators, enzymes, anti-oxidants, multivitamins, immunomodulators etc.^[5] Various herbal medicines are used for the treatment of OSMF. Considering the pathophysiology of the disease, the herbs having anti- inflammatory, fibrinolytic, anti-oxidant and anti- cancer properties must be used to get the expected result. Curcumin has a promising result in OSMF due to all the above mentioned properties.

1.1 Properties of curcumin

Curcumin is a polyphenol compound which is isolated from ground rhizomes of the *curcuma longa* plant of *Zingiberaceae* family found in South Asia. [6] Curcumin reduces inflammation by lowering histamine levels and increasing the production of natural cortisone by adrenalin gland. [7] Some researchers have shown that curcumin has a strong capability for scavenging superoxide radicals, hydrogen peroxide and nitricoxide from activated macrophages, reducing iron complex and inhibiting lipid peroxidation. It also has been shown to scavenge various reactive oxygen species produced by macrophages (including superoxide anions, hydrogen peroxide and nitrite radicals). These are the mechanisms by which curcumin exhibits its anti-oxidant properties. [8] Curcumin inhibit lipid peroxidation and check cellular proliferation, hence reduces the rate of collagen synthesis. This mechanism acts as a fibrinolytic property. [9] Curcumin increases levels of vitamin C and E thus prevents lipid peroxidation and DNA damage by decreasing the oxidation stress, hence have an anti-cancerous effect. [10] Curcumin has been used by many researchers to treat OSMF and found the significant result in various symptoms like burning sensation, restricted mouth opening etc.

This review has been done to analyse the clinical effectiveness of curcumin in oral submucous fibrosis.

2. Methodology

Literature search was done on the databases PubMed and Cochrane with the terms curcumin in oral submucous fibrosis. The articles published in the duration from 2011 to 2021 in English language are selected

2.1 Inclusion criteria

Only randomized control trials on use of curcumin in OSMF were included for this review

2.2 Exclusion criteria

Case reports, case series, observational studies, systemic reviews and meta-analysis were excluded from the study

2.3 Selection of studies

After screening of the articles, full texts of all the selected articles were read and after excluding some articles as per eligibility criteria few articles were selected for quality assessment

2.4 Quality Assessment

Quality assessment of selected articles was done by the quality assessment tool designed by Effective Public Health Practice Project. [11] which consists of six components – selection bias, study design, confounders, blinding, data collection method, withdrawal and dropouts

2.5 Outcome Assessed

The primary outcomes, like burning sensation, mouth opening and cheek flexibility were assessed.

3. Result

Total 110 studies were found relevant after searching in PubMed and Cochrane database out of which 80 were from PubMed and 30 were from Cochrane. After screening title and abstract total 8 studies were assessed for eligibility. Out of these studies 6 were excluded on the basis of not fulfilling eligibility criteria. Reasons for exclusion are summarized in Table 1. 2 studies finally selected for the qualitative analysis of the result. Quality assessment of the included studies is shown in **Table 2**. Out of these 2 studies 1 was found having high risk. At last only 1 study was found suitable for the quantitative synthesis of the result. The quantitative synthesis of the result is done as shown in **Table 3**. Data extraction is shown in **Figure 1**.

3.1 Quantitative Analysis

In the given study total 90 patients were included in age group ranging from 17 - 60 years out of which 70 were males and 30 were females. Patients were divided in 3 groups containing 30 patients each. Group A was given Tab Curcumin 300 mg twice a day. Group B was given Cap Lycopene 8 mg twice daily. Group C was given Placebo once a day. The duration of treatment was 6 months. After 3 months follow up was taken and no malignant transformation was observed during follow up. Assessment was done on the parameters like – burning pain, mouth opening and cheek flexibility. Burning pain was calculated on VAS (visual analogue scale). It was seen that mean was seen that curcumin group had significant improvement in these parameters as compared to the placebo group. (Table 4)

Figure 1: Flowchart of data extraction




Table 1. Excluded studies with reasons

| Author | Title of the study | Reason for exclusion | | |
|----------------------|--|---|--|--|
| name & | - | | | |
| year | | | | |
| Ashwini et | A comparative study to evaluate | Both groups were experimental, i.e. no | | |
| al, | efficacy of curcumin and aloe vera gel | placebo group was included | | |
| 2021 ^[12] | along with oral physiotherapy in the | | | |
| | management of oral submucous | | | |
| | fibrosis: A randomised clinical trial | | | |
| Lanjekar et | Comparison of efficacy of topical | All the three groups were experimental, | | |
| al, | curcumin gel with triamcinolone- | i.e. no placebo group was included | | |
| 2020 ^[13] | hyaluronidase gel individually and in | | | |
| | combination in the treatment of oral | | | |
| | submucous fibrosis | | | |
| Rai et al, | Comparative evaluation of curcumin | All the three groups were experimental, | | |
| 2019 ^[14] | and anti-oxidants in the management of | i.e. no placebo group was included | | |
| | submucous fibrosis | | | |
| Saran et al, | A comparative study to evaluate the | Both groups were experimental, i.e. no | | |
| $2018^{[15]}$ | efficacy of lycopene and curcumin in | | | |
| | oral submucous fibrosis patients: A | | | |
| | randomised clinic <mark>al trial</mark> | | | |
| Hazarey et | | The study was not randomised and Both | | |
| al, | for oral subm <mark>ucous</mark> fibrosis- A | 8-1-F | | |
| 2015 ^[16] | randomised clinical trial | placebo group was included | | |
| Yadav et al, | Comparison of curcumin with | Both groups were experimental, i.e. no | | |
| 2014 ^[17] | intralesional ster <mark>oid injections in oral</mark> | placebo group was included | | |
| | submucous fibrosis- A randomised open | | | |
| | label interventional study | | | |

Table 2 : Quality assessment

| Study | Overall | Selection | Study | Confounders | Data | Blinding | Withdrawal |
|------------------------------|------------|-----------|--------|-------------|------------|----------|------------|
| | quality | Bias | design | | collection | 10. | and |
| | assessment | | | | | 3 | dropout |
| Shah et al ^[18] | + | + + | + | +++ | + | + | + |
| Piyush et al ^[19] | + | + | + | + | + | + | + |

Low +, Moderate ++, High +++

Table 3: Study included for quantitative synthesis of result

| Author | Study groups | Age | Gender | Duration | Follow | Variables |
|-----------|-------------------------|------------|--------|----------|----------|-------------|
| | (no. of participants) | (Mean/rang | | | up | evaluated |
| | | e) | | | months | |
| Piyush et | Gr. A: Curcumin tablet | 32(17-60) | M-70 | 6 months | 3 months | Burning |
| al, | 300 mg twice daily | | F-20 | | | sensation, |
| 2019 | (n=30) | | | | | Mouth |
| | | | | | | opening, |
| | Gr. B : Lycopene | | | | | Cheek |
| | capsule | | | | | flexibility |
| | 8 mg twice daily | | | | | |
| | (n=30) | | | | | |
| | | | | | | |
| | Gr. C : Placebo capsule | | | | | |
| | once daily (n=30) | | | | | |

Table 4 – Quantitative Analysis

| | P value for difference | P value for difference | P value for difference | |
|-------------------|------------------------|------------------------|------------------------|--|
| | of burning pain | of mouth opening | of cheek flexibility | |
| | (VAS*) | | | |
| Group A & Group C | 0.0001 | 0.023 | 0.03 | |

^{*}VAS – Visual analogue scale

4. Discussion

Oral submucous fibrosis is a precancerous condition of buccal mucosa characterized by the restricted mouth opening. It is mainly associated with the habit of betel nut chewing mixed with tobacco and mainly affect the male population of low socioeconomic group in India. It affects the quality of life by hampering the activities like eating, swallowing and pronation due to fibrosis of oral mucosa. It also causes difficulty in brushing hence affects the oral hygiene causing other infective orodontal diseases. Various treatment modalities are opted for OSMF, but no definitive cure is found till date. Hence there is tremendous scope for research in this topic. Various studies have been carried out to prove the efficacy of curcumin in OSMF.

This review has searched many randomised control trials on use of curcumin in OSMF and after data extraction only one study was found to be eligible for the quantitative analysis. It is evident from the result of this study that the use of oral curcumin 600 mg daily has significant improvement in mouth opening, burning sensation and cheek flexibility in comparison to the placebo.

The possible properties by which curcumin is effective in OSMF is anti-fibrotic, anti-inflammatory, antioxidant and anti-carcinogenic.

It is suggested to perform more RCTs (randomised control trials) with large sample size and long duration of follow up to reach on the firm conclusion.

5. Conclusion

It is concluded from the result that oral curcumin is safe and effective treatment is oral submucous fibrosis.

References

- 1. Shun-Fa Yang et al, Submucous fibrosis from 1996 to 2013 in Taiwan: A nationwide population –based retrospective study, Journal of the Formosan Medical Association, 2018; 117(2):147-152, https://doi.org/10.1016/j.jfma.2017.01.012
- 2. Arakeri G. et al, Oral submucous fibrosis: An update on current theories of pathogenesis, Journal of oral pathology and medicine, 2017; 46:406-412, https://pubmed.ncbi.nlm.nih.gov/28391620.
- 3. Tilakaratne W.M., et al, Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral oncology.2006; 42:561-568, https://pubmed.ncbi.nlm.nih.gov/16311067
- 4. Wang Y.Y et al, Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 2014; 14: 99. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134123
- 5. Warnakulasuriya S. et al, Malignant transformation of oral leukoplakia: A systemic review of observational studies. Journal of oral pathology medicine.2016; 45:155-66, https://pubmed.ncbi.nlm.nih.gov/26189354
- 6. Borra S. K. et al, Effect of curcumin against oxidation of biomolecules by hydroxyl radicals. Journal of clinical and diagnostic research, 2014; 8(10), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253152

- 7. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in alzheimers disease animal models, Journal of Alzheimers disease, 2004; 6(4): 367-77, https://pubmed.ncbi.nlm.nih.gov/15345806
- 8. Joe B, et al, Biological properties of curcumin- cellular and molecular mechanism of action. Critical Reviews in Food Science and Nutrition, 2004; 44(2): 97-111, https://pubmed.ncbi.nlm.nih.gov/15116757
- 9. Agrawal N, et al, Evaluation of efficacy of turmeric in management of oral submucous fibrosis, Journal of Indian Academy of Oral Medicine and Radiology, 2014; 26(3):260-63, https://www.jiaomr.in/text.asp?2014/26/3/260/144998
- 10. Rai B, Possible action mechanism for curcumin in precancerous lesions based on serum and salivary markers of oxidative stress. Journal of Oral Science.2010; 52(2):251-56, https://pubmed.ncbi.nlm.nih.gov/20587949
- 11. Evans N.A Systematic Review of Rural Development Research. East Africa: Springerbriefs in Public Health; 2015 [Google scholar]
- 12. Ashwini et al, A comparative study to evaluate efficacy of curcumin and aloe vera gel along with oral physiotherapy in the management of oral submucous fibrosis: A randomised clinical trial. Asian Pacific Journal of Cancer Prevention, 2021; 22(S1):107-112, https://pubmed.ncbi.nlm.nih.gov/33576219
- 13. Lanjekar et al, Comparison of efficacy of topical curcumin gel with triamcinolone-hyaluronidase gel individually and in combination in the treatment of oral submucous fibrosis, The Journal of Contemporary Dental Practice, 2020;21(1): 83-90, https://pubmed.ncbi.nlm.nih.gov/32381807
- 14. Rai et al, Comparative evaluation of curcumin and anti-oxidants in the management of submucous fibrosis, Journal of Investigative and Clinical Dentistry, 2019;10(4), https://pubmed.ncbi.nlm.nih.gov/31605442
- 15. Saran et al, A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: A randomised clinical trial, Indian Journal of Dental Research, 2018; 19(3):303-312, https://pubmed.ncbi.nlm.nih.gov/29900913
- 16. Hazarey et al, Efficacy of curcumin in the treatment for oral submucous fibrosis- A randomised clinical trial, Journal of Oral and Maxillofacial Pathology, 2015;19(2):145-152, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611920
- 17. Yadav et al, Comparison of curcumin with intralesional steroid injections in oral submucous fibrosis- A randomised open label interventional study, Journal of Oral Biology and Craniofacial Research, 2014;4(3): 169-173, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306996
- 18. Shah et al, Comparison of systemic and topical forms of curcumin in oral submucous fibrosis: A clinical and histopathological evaluation in 120 patients, International Journal of Oral Care and Research, 2018; 6(3): 1-4, https://www.ijocr.org/article.asp?issn=2347-6249
- 19. Piyush et al, Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized control trial, Oral Diseases, 2019;25(1):73-79, https://pubmed.ncbi.nlm.nih.gov/30059188